The use of trastuzumab in New Zealand women with breast cancer.

Ross LawrensonChunhuan LaoIan CampbellVernon HarveyCharis BrownSanjeewa SeneviratneMelissa EdwardsMark ElwoodMarion Kuper-Hommel

Published in: Asia-Pacific journal of clinical oncology (2017)

Overall, this observational study has shown a substantial improvement in survival for women with HER2+ve stage I-III breast cancer, and much of this improvement can be attributed to the introduction of trastuzumab. Changes in chemotherapy also appear to have led to improved outcomes.

Keyphrases

epidermal growth factor receptor
metastatic breast cancer
locally advanced
tyrosine kinase
metabolic syndrome
young adults
rectal cancer